Literature DB >> 1691655

An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease.

S McClinton1, I D Miller, O Eremin.   

Abstract

The prostate gland is said to be immunologically privileged because it lacks afferent lymphatics and because of the immunosuppressive properties of seminal fluid. To elicit the presence or absence of an immune response within the diseased prostate gland, the infiltrate in prostate glands affected by hyperplasia or adenocarcinoma was phenotypically characterised, using immunohistochemical techniques. An infiltrate, composed mainly of T-lymphocytes (CD-3+), was demonstrated in all glands examined. No difference in the type, level of activation or degree of infiltration was found between those glands affected by hyperplasia (n = 20) and those affected by adenocarcinoma (n = 20). In the malignant cases, there was no correlation between grade (Gleason) or stage (TNM) and the type or degree of mononuclear cell infiltrate. Our findings suggest that the host response, in situ, to hyperplasia and adenocarcinoma is similar and may reflect the fact that the two diseases are often found concurrently in the same gland and in close proximity to one another. The infiltrate, therefore, is unlikely to represent a tumour specific immune response to tumour specific antigens. The significant infiltrate we have demonstrated, and its phenotypic characterisation, would not support the hypothesis that the prostate is immunologically privileged as has been suggested previously.

Entities:  

Mesh:

Year:  1990        PMID: 1691655      PMCID: PMC1971287          DOI: 10.1038/bjc.1990.87

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  The human interleukin-2 receptor.

Authors:  W C Greene; W J Leonard
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

2.  Interleukin-2 receptor expression in benign and malignant melanocytic skin lesions.

Authors:  N M Kernohan; H F Sewell
Journal:  J Pathol       Date:  1989-04       Impact factor: 7.996

3.  Studies on the immunosuppressive effect of seminal plasma.

Authors:  A J Quayle; S Szymaniec; T B Hargreave; K James
Journal:  Br J Urol       Date:  1987-12

4.  Origin and development of carcinoma in the prostate.

Authors:  J E McNeal
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

Review 5.  Immunologic mechanisms in intestinal diseases.

Authors:  S R Targan; M F Kagnoff; M D Brogan; F Shanahan
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

6.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

7.  Carcinoma of the prostate in patients 70 to 79 years old.

Authors:  B Halpert; W R Schmalhorst
Journal:  Cancer       Date:  1966-05       Impact factor: 6.860

8.  The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

Authors:  T A Waldmann
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

Review 9.  Human tumor-infiltrating lymphocytes: a marker of host response.

Authors:  B M Vose; M Moore
Journal:  Semin Hematol       Date:  1985-01       Impact factor: 3.851

Review 10.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review.

Authors:  J C Underwood
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

View more
  10 in total

Review 1.  Human microbiome and prostate cancer development: current insights into the prevention and treatment.

Authors:  Solmaz Ohadian Moghadam; Seyed Ali Momeni
Journal:  Front Med       Date:  2020-06-30       Impact factor: 4.592

2.  MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.

Authors:  Navreet K Nanda; Lynn Birch; Norman M Greenberg; Gail S Prins
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

Review 3.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

4.  Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.

Authors:  W Nathaniel Brennen; Charles G Drake; John T Isaacs
Journal:  Cancer Res       Date:  2014-04-18       Impact factor: 12.701

Review 5.  Immune Checkpoint Therapies in Prostate Cancer.

Authors:  Sangeeta Goswami; Ana Aparicio; Sumit K Subudhi
Journal:  Cancer J       Date:  2016 Mar-Apr       Impact factor: 3.360

6.  Impaired access of lymphocytes to neoplastic prostate tissue is associated with neoangiogenesis in the tumour site.

Authors:  S Fedida; D Fishman; Z Suzlovich; S Argov; M Friger; L Oren; S Segal; N Sion-Vardy
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

7.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.

Authors:  Bettina Schlick; Petra Massoner; Angelika Lueking; Pornpimol Charoentong; Mirjam Blattner; Georg Schaefer; Klaus Marquart; Carmen Theek; Peter Amersdorfer; Dirk Zielinski; Matthias Kirchner; Zlatko Trajanoski; Mark A Rubin; Stefan Müllner; Peter Schulz-Knappe; Helmut Klocker
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 8.  Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.

Authors:  Jennifer L Kalina; David S Neilson; Alexandra P Comber; Jennifer M Rauw; Abraham S Alexander; Joanna Vergidis; Julian J Lum
Journal:  Cancers (Basel)       Date:  2017-01-27       Impact factor: 6.639

Review 9.  Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.

Authors:  Tommaso Cai; Raffaella Santi; Irene Tamanini; Ilaria Camilla Galli; Gianpaolo Perletti; Truls E Bjerklund Johansen; Gabriella Nesi
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

10.  Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo.

Authors:  Anna Le Tortorec; Anne-Pascale Satie; Hélène Denis; Nathalie Rioux-Leclercq; Laurence Havard; Annick Ruffault; Bernard Jégou; Nathalie Dejucq-Rainsford
Journal:  Retrovirology       Date:  2008-12-31       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.